Immunovia AB is a cutting-edge Healthcare company based in Sweden with a high-risk ESG score of 32.2. Specializing in molecular diagnostics, they develop innovative tools for cancer and autoimmune disease diagnosis. Their IMMray technology platform, utilizing antibody microarray analysis, is at the forefront of early detection research. Currently, Immunovia AB is pioneering a next-generation blood test for the detection of pancreatic cancer in high-risk individuals. Optimize your healthcare strategy with Immunovia AB's advanced ESG-certified diagnostic solutions.